Virica Biotech
Virica was founded in 2018 based on a decade of research in the laboratory of Dr. Jean-Simon Diallo at the Ottawa Hospital Research Institute. Dr. Diallo was investigating novel oncolytic viral therapies (OVTs) and recognized the need for VSEs to enhance the effectiveness of OVTs. After researching and developing VSEs in the OVT space, Dr. Diallo recognized how broadly applicable their attributes would be in other areas like gene therapy and vaccine production. Recent influenza outbreaks and the COVID-19 pandemic highlight the need for scalability in the production of vaccines. Virica has the products and experience to combat these challenges.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
- Year Founded:
- 2018
- Employees:
- 11-100
About Us
Viral Sensitizers
Unlock Your Potential to Increase Yield and Effectiveness
We believe viral medicines are the way of the future
Viral medicines include gene therapies, vaccines and oncolytic viruses. We understand the barriers holding drug developers and manufacturers back from achieving the potential of your products and services. Our proprietary and pioneering Viral Sensitizers (VSE™) unlock the potential to increase yield and effectiveness at better margins.
We help you positively change human health
From viral medicines manufacturing to anti-cancer therapy, Virica addresses unmet needs in production and development to positively change human health. Our VSEs improve and optimize your processes to deliver high-yield products at a lower unit cost.
Scientific insights from Virica
We offer you insightful and educational resources to enhance your scientific knowledge of viral medicine development and production.
Our purpose is to realize the promise of viral medicines, thereby extending the horizons of human healthcare
We pioneered a new product category of Viral Sensitizers that removes the barriers to achieve scalability and effectiveness in the production of viral medicines. Customized VSE formulations optimize research processes and enhance production. VSEs help bring your treatments to patients on an accelerated timeline.
Be a contributing member of a hyper-growth biotechnology company
Check in often to read about our career opportunities.